Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. - de Wit,R.; Herrstedt,J.; Rapoport,B. (J Clin Oncol, 2003)